Relmada Therapeutics (RLMD) has had the highest return since January 1, 2025 by a US stock in the Pharmaceuticals Industry, returning 412.7%.
| ASSET | % RETURN |
|---|---|
Relmada Therapeutics (RLMD) | 412.72% |
Nektar Therapeutics (NKTR) | 321.46% |
NovaBay Pharmaceuticals (NBY) | 292.31% |
Amylyx Pharmaceuticals (AMLX) | 250.66% |
Sol Gel Technologies (SLGL) | 210.53% |
Durect (DRRX) | 154.67% |
Xeris Pharmaceuticals (XERS) | 145.13% |
Trevi Therapeutics (TRVI) | 130.92% |
Verona Pharma PLC ADR (VRNA) | 128.64% |
Elicio Therapeutics (ELTX) | 122.74% |
Tvardi Therapeutics (TVRD) | 114.4% |
Hoth Therapeutics (HOTH) | 106.21% |
Fulcrum Therapeutics (FULC) | 98.13% |
Phibro Animal Health (PAHC) | 86.28% |
Liquidia Technologies (LQDA) | 85.44% |
Eyepoint Pharmaceuticals (EYPT) | 77.87% |
Talphera (TLPH) | 77.58% |
Corcept Therapeutics (CORT) | 68.87% |
Elanco Animal Health (ELAN) | 67.51% |
Maze Therapeutics, Inc Common Stock (MAZE) | 65.63% |
Adagio Medical Holdings, Inc Common Stock (ADGM) | 64.75% |
SIGA Technologies (SIGA) | 60.98% |
ANI Pharmaceuticals (ANIP) | 60.31% |
Aquestive Therapeutics (AQST) | 60.28% |
Ventyx Biosciences (VTYX) | 59.01% |
